In a recent study posted to the medRxiv* preprint server, researchers explored severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern/interest (VOC/VOI) kinetics and variations among non-hospitalized acute coronavirus disease 2019 (COVID-19) patients.
Study: Duration of viral infectiousness and correlation with symptoms and diagnostic testing in non-hospitalized adults during acute SARS-CoV-2 infection: A longitudinal cohort study. Image Credit: creativeneko/Shutterstock
This news article was a review of a preliminary scientific report that had not undergone peer-review at the time of publication. Since its initial publication, the scientific report has now been peer reviewed and accepted for publication in a Scientific Journal. Links to the preliminary and peer-reviewed reports are available in the Sources section at the bottom of this article. View Sources
Background
COVID-19 prevention recommendations have been based on limited data on SARS-CoV-2 transmissibility duration and correlation with COVID-19 symptomatology and diagnostic testing. Effective diagnostic techniques are essential for viral detection, SARS-CoV-2 transmission curtailment, and informing poly-makers for improved global public health.
About the study
In the present study, researchers evaluated the SARS-CoV-2 transmissibility duration, correlation with SARS-CoV-2 infection symptoms, and SARS-CoV-2 testing among non-hospitalized COVID-19 patients.
Ambulatory adult patients with acute SARS-CoV-2 infections not requiring hospitalizations were enrolled for the study, and serial COVID-19 symptom measurements were performed. COVID-19 diagnosis was confirmed by reverse transcription-polymerase chain reaction (RT-PCR) analysis of nasopharyngeal (NP) swab samples within a week of enrollment. Participants were asked to complete comprehensive questionnaires to obtain data on the onset and duration of COVID-9 symptoms.
Follow-up assessments were performed at five different time points, and at each follow-up visit, anterior nasal (AN) swabs, NP swabs, and serum samples were obtained from the participants. The NP swabs were subjected to RT-PCR analysis for viral load determination. The mean duration between symptom onset and the initial SARS-CoV-2-negative test report was determined, and the transmissibility risks were estimated based on positive viral cultures.
Only individuals without prior COVID-19 history and those who didn’t receive COVID-19 vaccinations were included in the analysis. The team excluded individuals who were child-bearing, suffered from immunosuppressive medical conditions [e.g., human immunodeficiency virus (HIV) acquired immunodeficiency syndrome (AIDS), diabetes mellitus type 1, rheumatoid arthritis, multiple sclerosis, and lupus), or were on immunomodulators or glucocorticoid medications, or participated in interventional SARS-CoV-2 infection clinical trials.
Swabs from the anterior nasal (AN) regions were analyzed for the presence of SARS-CoV-2 ribonucleic acid (RNA), spike (S), and nucleocapsid (N) proteins using electrochemiluminescence immunoassays. Serum samples obtained from the participants were assessed for total [immunoglobulin M (IgM), IgA, IgG] anti-SARS-CoV-2 S titers and anti-SARS-CoV-2 S IgG titers by chemiluminescent immunoassays. Cell culture experiments were performed using Vero E6 cells that expressed transmembrane serine protease 2 and human angiotensin-converting enzyme 2 (hACE2) for SARS-CoV-2 growth assessment.
SARS-CoV-2-inoculated cells were microscopically examined for cell death and/or syncytia formation over 10 days. The culture isolates were subjected to whole genome sequencing (WGS) analysis using the SARS-CoV-2 Wuhan-Hu-1 strain for reference. Relative risk (RR) estimates for culture positivity were obtained, with data adjustments for sex, age, variant, and comorbidities.
Results
A total of 95 adults were analyzed, among whom, median values for the duration between symptom and the first SARS-CoV-2-negative test report were nine days, 13 days, 11 days, and >19 days for viral S, N, culture growth, and SARS-CoV-2 RNA, respectively. The study mainly comprised young individuals (median age of 29 years), and 43% of them were women. Beyond 15 days, cultures and SARS-CoV-2 N titers were rarely positive, whereas SARS-CoV-2 RNA by RT-PCR remained above detectable levels among 26 (out of 51) participants tested after 21 days to 30 days of COVID-19 symptom onset.
Six to 10 days post-symptom onset, SARS-CoV-2 N showed a strong association with cultures (RR 7.6). Fourteen days post-symptom onset, SARS-CoV-2 N presence (adjusted RR 7.7) remained to be strongly associated with positive SARS-CoV-2 cultures, irrespective of symptoms. Nine, 22, and one patient were infected with the Alpha VOC, Epsilon VOI, and Gamma VOC, respectively, whereas 28 patients were infected with a non-VOC/VOI virus. SARS-CoV-2 N presence was strongly associated with a higher risk of transmissibility (aRR=7.7).
Most (80%) samples showed SARS-CoV-2 positivity in the RT-PCR, culture, and SARS-CoV-2 N positivity tests in the initial five days post-symptom onset. Between six to 10 days post-symptom onset, 96% of samples were RT-PCR-positive, 79% of patients showed N positivity, and 41% of samples showed culture positivity. Between 11 to 15 days post-symptom onset, 85% (n=82) were RT-PCR-positive and culture negative, of which 39% showed antigen positivity. Among all participants, symptoms such as fever, pulmonary symptoms, and smell/taste loss were not associated significantly with SARS-CoV-2 transmissibility in the initial two weeks after the onset of COVID-19 symptoms.
Conclusion
Overall, the study findings showed that most non-hospitalized COVID-19 patients had replication-competent SARS-CoV-2, indicative of viral transmissibility for 10 to 14 days post-symptom onset, which SARS-CoV-2 N tests could effectively estimate. Thus, SARS-CoV-2 N testing 14 days post-symptom onset should be used for the safe discontinuation of isolation.
This news article was a review of a preliminary scientific report that had not undergone peer-review at the time of publication. Since its initial publication, the scientific report has now been peer reviewed and accepted for publication in a Scientific Journal. Links to the preliminary and peer-reviewed reports are available in the Sources section at the bottom of this article. View Sources
Article Revisions
- May 16 2023 - The preprint preliminary research paper that this article was based upon was accepted for publication in a peer-reviewed Scientific Journal. This article was edited accordingly to include a link to the final peer-reviewed paper, now shown in the sources section.
Phase 2 study evaluates safety and efficacy of asunercept in COVID-19 patients